Background: Rheumatoid arthritis (RA) is an autoimmune disease that affects joints and can have extra-articular manifestations. RA usually tends to be progressive and leads to substantial health care burdens, both in terms of disability and economic costs. Despite the various treatment modalities available, there is still an urgent need for safe and effective medicine based on the pattern of disease presentation. The increasing interest in complementary and alternative medicine has created a demand for extensive research in this area. Objective: This clinical study is designed to evaluate the effectiveness and tolerability of a composite Ayurveda regimen in RA. Methods: The study is a single-arm (pre-post design), community-based interventional study with a black box design being conducted at 6 study centers. A total of 240 participants aged between 18 and 65 years, diagnosed with RA as per the 2010 American College of Rheumatology and the European League Against Rheumatism criteria are recruited as per the selection criteria. All the participants received Ayush-SG and Rasnasaptak Kashaya for 84 days along with customized treatment as per the disease presentation and associated complaints. The outcome measures include the change in disease activity score (DAS)-28 with erythrocyte sedimentation rate, disease-specific biochemical and inflammatory markers, Disability Index score, change in the participant’s assessment of pain and frequency of use of conventional analgesics or nonsteroidal anti-inflammatory drugs from baseline. The tolerability of interventions is assessed through the occurrence of adverse events. Categorical variables will be analyzed with McNemar chi-square test, and continuous variables will be assessed using the paired t test or Wilcoxon test for pre-post assessment. The level of significance will be 5%. Results: The recruitment of participants was initiated in December 2023. The participant recruitment was completed in March 2024 and out of 240 participants enrolled, 222 (92.5%) completed the study up to the last follow-up. Data verification, compilation, and analysis are under process. After data analysis, the study’s findings will be published in a peer-reviewed journal. Conclusions: This interventional study that incorporates the black box approach may provide a strong framework for managing RA. This design is a more reliable method for evaluating the effectiveness and tolerability of the composite Ayurveda regimen in RA. Trial Registration: Clinical Trial Registry-India CTRI/2023/06/054203; https://tinyurl.com/4prvwr6z International Registered Report Identifier (IRRID): DERR1-10.2196/57918
Background: With advancing age among older adults, the associated debilities increase, indicating a deteriorating health status as there is a gradual loss of muscle mass, strength, and functionality. Ayush Rasayana A and B are coded Ayurvedic medicines developed from herbal extracts. This study has been planned to prevent debilitating conditions and improve the quality of life (QOL) in older adults. Objective: This study aimed to assess the effectiveness of Ayush Rasayana A and B on the QOL, quality of sleep, and functionality of older adults, along with the tolerability of the intervention. Methods: This was a multicenter, open-label, cluster randomized controlled trial conducted with 720 participants aged 60 to 75 years. The participants were divided into 2 groups (intervention and control), with both receiving Ayurvedic ancillary treatment for 3 months. The intervention group additionally received 10 g of Ayush Rasayana A orally once daily at bedtime for 6 days, followed by 1.5 g of Ayush Rasayana B orally twice daily before food for the remaining 84 days. The assessment criteria included the Older People’s Quality of Life Questionnaire Brief, Katz Index of Independence in Activities of Daily Living, Pittsburgh Sleep Quality Index, Five Times Sit-to-Stand Test, and shoulder and scapular movements. Any change in hematological and biochemical parameters and occurrence of treatment-emergent adverse events were also assessed during the study period. Results: The recruitment of the participants started in December 2023, and the final follow-up was completed in April 2024. Out of the total 720 enrolled participants, 686 (95.3%) completed the study up to the last follow-up. Conclusions: This study may provide evidence-based data to establish preventive treatment protocols for enhancing the QOL and functionality among older adults. The study results may also be helpful for the planning of interdisciplinary health policies for improving the health conditions of different populations International Registered Report Identifier (IRRID): DERR1-10.2196/58186
1 July 2024 in Journal of Research in Ayurvedic Sciences
BACKGROUND: Primary dysmenorrhea is one of the major public health concerns that affects about 50%–90% of women. Even though the condition is associated with psychosomatic symptoms, conventional management is mainly focused on reducing pain only. This study is designed to evaluate the potential of Ayurvedic management in dysmenorrhea, addressing both physical and psychosomatic aspects of the condition. OBJECTIVE: The study aims to assess the effectiveness and tolerability of Rajapravartani Vati and Saraswatarishta in dysmenorrhea. MATERIALS AND METHODS: This study is a prospective, single-arm, open-label, and multicenter clinical study involving 10 centers. According to pre-defined selection criteria, a total of 460 participants with primary dysmenorrhea in the age range of 14–25 years will be enrolled from the study sites. All participants will receive Rajapravartani Vati 500 mg twice daily orally starting from 7 days before the expected date of the menstrual cycle up to the third day of menstruation for three consecutive menstrual cycles. Saraswatarishta will be given, a 10 mL dose with 20 mL of lukewarm water at bedtime for 84 days. The participants will be followed for further 3 months to assess the sustained effect of the intervention. The change in pain, disease-specific symptoms, and psychosomatic status will be assessed for three consecutive cycles by using the Visual Analog Scale score, Working Ability, Location, Intensity, Days of pain, Dysmenorrhea score, and Moos Menstrual Distress Questionnaire, respectively. The tolerability of the drugs will be assessed through the occurrence of treatment-emergent adverse events during the study period, and compliance to study interventions. DISCUSSION: This study will help in providing evidence-based scientific data related to the clinical evaluation and tolerability of Rajapravartani Vati and Saraswatarishta in dysmenorrhea. TRIAL REGISTRATION: CTRI/2023/07/054617 dated July 3, 2023.
BACKGROUND Menstruation remains a taboo subject in many developing countries, leading to a lack of awareness and inadequate hygiene practices. Scheduled Caste (SC) women are one of the most socio-culturally deprived groups, often facing barriers to education and essential healthcare resources. Limited educational opportunities limit their awareness of proper menstrual hygiene, making them more likely to adopt unhygienic practices. Despite this vulnerability, information on their knowledge, attitudes and practices (KAP) related to menstruation, including Rajaswala Paricharya (guidelines to be followed during menstruation), remains scarce. OBJECTIVE The primary objective of this study is to estimate KAP regarding menstruation among Scheduled Castes women of reproductive age. The secondary objectives are to explore variations in KAP across different geographical regions and reproductive age groups, and to examine the influence of the education and occupation of the participants and their mothers on KAP. METHODS This multi-centre, community-based, cross-sectional study has been conducted in areas predominantly inhabited by the SC community. The women aged 15–49 who provide informed consent/assent have been enrolled in the study. Data have been collected through face-to-face interviews using a pre-tested and validated KAP questionnaire. RESULTS A total of 1,400 participants were enrolled in the study through a door-to-door survey. This paper represents the baseline protocol; the detailed analysis and results will be reported in a subsequent publication. CONCLUSIONS This study will estimate the current status of menstrual KAP including Rajaswala Paricharya (RP) among Scheduled Caste women. Furthermore, the findings are expected to serve as a foundation for the development of targeted public health strategies and the design of equitable, culturally sensitive menstrual health interventions
BACKGROUND With advancing age among older adults, the associated debilities increase, indicating a deteriorating health status as there is a gradual loss of muscle mass, strength, and functionality. Ayush Rasayana A and B are coded Ayurvedic medicines developed from herbal extracts. This study has been planned to prevent debilitating conditions and improve the quality of life (QOL) in older adults. OBJECTIVE This study aimed to assess the effectiveness of Ayush Rasayana A and B on the QOL, quality of sleep, and functionality of older adults, along with the tolerability of the intervention. METHODS This was a multicenter, open-label, cluster randomized controlled trial conducted with 720 participants aged 60 to 75 years. The participants were divided into 2 groups (intervention and control), with both receiving Ayurvedic ancillary treatment for 3 months. The intervention group additionally received 10 g of Ayush Rasayana A orally once daily at bedtime for 6 days, followed by 1.5 g of Ayush Rasayana B orally twice daily before food for the remaining 84 days. The assessment criteria included the Older People’s Quality of Life Questionnaire Brief, Katz Index of Independence in Activities of Daily Living, Pittsburgh Sleep Quality Index, Five Times Sit-to-Stand Test, and shoulder and scapular movements. Any change in hematological and biochemical parameters and occurrence of treatment-emergent adverse events were also assessed during the study period. RESULTS The recruitment of the participants started in December 2023, and the final follow-up was completed in April 2024. Out of the total 720 enrolled participants, 686 (95.3%) completed the study up to the last follow-up. CONCLUSIONS This study may provide evidence-based data to establish preventive treatment protocols for enhancing the QOL and functionality among older adults. The study results may also be helpful for the planning of interdisciplinary health policies for improving the health conditions of different populations INTERNATIONAL REGISTERED REPORT DERR1-10.2196/58186
BACKGROUND Rheumatoid arthritis (RA) is an autoimmune disease that affects joints and can have extra-articular manifestations. RA usually tends to be progressive and leads to substantial health care burdens, both in terms of disability and economic costs. Despite the various treatment modalities available, there is still an urgent need for safe and effective medicine based on the pattern of disease presentation. The increasing interest in complementary and alternative medicine has created a demand for extensive research in this area. OBJECTIVE This clinical study is designed to evaluate the effectiveness and tolerability of a composite Ayurveda regimen in RA. METHODS The study is a single-arm (pre-post design), community-based interventional study with a black box design being conducted at 6 study centers. A total of 240 participants aged between 18 and 65 years, diagnosed with RA as per the 2010 American College of Rheumatology and the European League Against Rheumatism criteria are recruited as per the selection criteria. All the participants received Ayush-SG and Rasnasaptak Kashaya for 84 days along with customized treatment as per the disease presentation and associated complaints. The outcome measures include the change in disease activity score (DAS)-28 with erythrocyte sedimentation rate, disease-specific biochemical and inflammatory markers, Disability Index score, change in the participant’s assessment of pain and frequency of use of conventional analgesics or nonsteroidal anti-inflammatory drugs from baseline. The tolerability of interventions is assessed through the occurrence of adverse events. Categorical variables will be analyzed with McNemar chi-square test, and continuous variables will be assessed using the paired t test or Wilcoxon test for pre-post assessment. The level of significance will be 5%. RESULTS The recruitment of participants was initiated in December 2023. The participant recruitment was completed in March 2024 and out of 240 participants enrolled, 222 (92.5%) completed the study up to the last follow-up. Data verification, compilation, and analysis are under process. After data analysis, the study’s findings will be published in a peer-reviewed journal. CONCLUSIONS This interventional study that incorporates the black box approach may provide a strong framework for managing RA. This design is a more reliable method for evaluating the effectiveness and tolerability of the composite Ayurveda regimen in RA. CLINICALTRIAL Clinical Trial Registry-India CTRI/2023/06/054203; https://tinyurl.com/4prvwr6z INTERNATIONAL REGISTERED REPORT DERR1-10.2196/57918